Changes in palmitate- and stearate-containing glycerophospholipids in skeletal muscle during clenbuterol-induced fast-twitch fiber transition and hypertrophy Authors: Yuna Suzuki, Tomoki Sato, Satoshi Ohuchi, Sango Nakashima, Noriyuki Miyoshi, Shinji Miura Published: 2026 ABSTRACT AbstractFast- and slow-twitch skeletal muscle fibers exhibit distinct glycerophospholipid compositions, and slow-twitch transition is accompanied by characteristic changes in glycerophospholipid molecular species. However, whether glycerophospholipid composition is remodeled during fast-twitch fiber transition and skeletal muscle hypertrophy remains unclear. In this study, we examined changes in palmitate- and stearate-containing glycerophospholipids using a mouse model of clenbuterol-induced fast-twitch transition and hypertrophy. Clenbuterol administration increased the proportion of fast-twitch fibers and induced skeletal muscle hypertrophy. Lipidomic analysis revealed a significant increase in palmitate-containing phosphatidylcholine and a decrease in stearate-containing phosphatidylcholine in the tibialis anterior and soleus muscles. Consistent with these glycerophospholipid alterations, the expression of several acyltransferases, such as glycerol-3-phosphate acyltransferase 3 (GPAT3), involved in glycerophospholipid acyl-chain determination was significantly altered. These findings demonstrate that glycerophospholipid composition is remodeled during fast-twitch fiber transition and muscle hypertrophy, highlighting lipid remodeling as a component of skeletal muscle phenotypic adaptation.Keywords: Muscle, Glycerophospholipid, Phosphatidylcholine, Muscle hypertrophy, Fast-twitch fiber transition, Clenbuterol Introduction It is well established that exercise training improves skeletal muscle function. Endurance exercise training performed at approximately 60–80% VO2max intensity enhances aerobic capacity due to an increase in mitochondrial content, fatty acid oxidation, and angiogenesis in skeletal muscle [1], [2]. Such training also promotes a shift in muscle fiber composition from fast-twitch to slow-twitch fibers, such as from type IIb fiber to type IIx or IIa fibers, leading to a more oxidative muscle phenotype [3], [4]. In contrast, resistance training primarily enhances anaerobic performance and induces hypertrophy of fast-twitch muscle fibers [5], [6]. Glycerophospholipids are fundamental lipid components required for the structural integrity of cellular membranes and display remarkable molecular diversity due to variations in acyl chain composition and polar head groups [7]. Recent studies have revealed that glycerophospholipid molecular diversity differs among organs [7], [8], and a characteristic glycerophospholipid composition unique to skeletal muscle has been identified [9], [10]. When skeletal muscle is classified into fast-twitch and slow-twitch fibers, the extensor digitorum longus (EDL), which contains a large number of fast-twitch fibers such as type IIx and type IIb fibers [11], is characterized by a high abundance of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) species containing palmitate as an acyl chain (16:0-PC and PE). In contrast, the soleus, which is composed of many slow-twitch fibers such as type I and type IIa fibers, contain not only 16:0-PC and PE species but also stearate-containing species (18:0-PC and PE) [9]. Moreover, in fast-twitch fibers that undergo an acquired slow-twitch transition induced by overexpression of proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), the abundance of 18:0-PC and PE is increased [9]. These observations suggest that changes in skeletal muscle phenotype are accompanied by alterations in glycerophospholipid contained palmitate and stearate. While endurance exercise induces slow-twitch transition of skeletal muscle, resistance exercise primarily promotes hypertrophy of type II fibers [12]. Pharmacological administration of the β₂-adrenergic agonist clenbuterol similarly induces skeletal muscle hypertrophy [13], [14]. In addition, clenbuterol decreases the proportion of type I fiber and increases the proportion of type IIb fiber [15], [16], [17], [18], [19]. Although previous studies have demonstrated that glycerophospholipid molecular species change during slow-twitch transition of skeletal muscle, it remains unclear whether glycerophospholipid composition is also remodeled during fast-twitch fiber transition and muscle hypertrophy. We therefore hypothesized that fast-twitch transition and skeletal muscle hypertrophy are accompanied by remodeling of glycerophospholipid acyl-chain composition. To test this hypothesis, we analyzed changes in palmitate- and stearate-containing glycerophospholipids in skeletal muscles from mice treated with clenbuterol. Methods Experimental animals Male C57BL/6 J mice (6 weeks-old) obtained from Japan SLC, Inc. (Shizuoka, Japan) were used for all experiments. Mice were maintained in a 12 h light/dark cycle at 22 °C and fed a normal chow diet (CE-2; CLEA Japan, Inc., Tokyo, Japan) ad libitum. Mice were cared for in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and our institutional guidelines. All animal experiments were conducted with the approval of the Institutional Animal Care and Use Committee of the University of Shizuoka (number 245465). Four weeks clenbuterol administration After one week of acclimation, mice were randomly assigned to a control (Control, n = 6–7) or clenbuterol-treated group (Clenbuterol, n = 6) with comparable body weights. Based on previously reported experiments [15], [16], [17], [18], [19], the clenbuterol group received clenbuterol (Sigma-Aldrich, St. Louis, MO, USA) in drinking water containing 20 mg/L of clenbuterol (0.02% ethanol) for 4 weeks, whereas the Control group received vehicle (0.02% ethanol). After treatment, mice were sacrificed by cervical dislocation, and tissue samples were collected and stored at −80 °C until analysis. Single dose clenbuterol administration After one week of acclimation, male mice were randomly assigned to either a group receiving a single dose of vehicle (Single Control, n = 5) or a group receiving a single dose of clenbuterol (Single Clenbuterol, n = 5). Single Clenbuterol group received subcutaneous injection of clenbuterol (1 mg/kg body weight), whereas the Single Control group received an equivalent volume of vehicle (0.02% ethanol). Six hours after treatment, mice were sacrificed by cervical dislocation, and tissue samples were collected and stored at −80 °C until analysis. Grip strength test Grip strength was measured using a grip strength meter GPM-100B (Melquest, Toyama, Japan). Mice were allowed to grasp a wire mesh with all four limbs, and their tails were gently pulled backward until the limbs were released from the instrument. The maximum tension value (kg) was recorded for each measurement. Each mouse was tested twice, and the mean value was used for analysis. Immunohistochemical analysis of muscle cryosections Muscle cryosectioning, immunohistochemistry, and fiber-type analysis were performed as previously described [9]. Briefly, tibialis anterior (TA) muscles were rapidly frozen in isopentane cooled with liquid nitrogen, and 10-μm transverse cryosections were prepared. Sections were acetone-fixed, blocked, and incubated with antibodies against myosin heavy chain (MyHC) isoforms (type I, IIa, and IIb) and laminin (Table S1), followed by Alexa Fluor-conjugated secondary antibodies (Table S2). Fluorescent images were acquired using a Leica fluorescence microscope (DMi8, Leica Microsystems, Wetzlar, Germany). Muscle fiber types and cross-sectional area (CSA) were determined separately in the deep and superficial regions of laminin-stained sections using merged immunofluorescence images. Approximately 200 fibers per section, covering a total area of 2.6 × 10⁵ µm², were analyzed using WinROOF 2018 (Mitani Corporation, Fukui, Japan). Mean CSA values were calculated for each animal and used for statistical comparisons between groups. CSA distributions were visualized as histograms constructed from pooled fiber measurements within each experimental group. Because histograms represent fiber-level frequency distributions rather than individual animal-level statistics, variability measures such as standard error of the mean (SEM) were not displayed [15]. Analysis of glycerophospholipid species in skeletal muscles by liquid chromatograph-mass spectrometry (LC-MS) Glycerophospholipid analysis of skeletal muscles was performed as previously described [9]. Briefly, frozen TA and soleus muscle was powdered in liquid nitrogen, and total lipids were extracted using chloroform/methanol containing internal standards. Lipid extracts were reconstituted and filtered prior to analysis. The PC and PE species were analyzed using an LCMS-8040 triple quadrupole mass spectrometer (Shimadzu Corporation, Kyoto, Japan) equipped with an electrospray source ionization probe, LC-30AD binary pump (Shimadzu), SIL-30AC auto sampler (Shimadzu), and CTO-20AC column oven (Shimadzu). Accucore RP-MS column (2.6 μm, 2.1 mm×50 mm; Thermo Fisher Scientific Inc., Waltham, MA, USA) was used for high-performance liquid chromatography analysis. PC and PE were quantified using multiple reaction monitoring (MRM) in negative ionization mode, in which detection of fatty acid fragments was set for Q3. Details of the LC-MS parameter and the MRM conditions are listed in Tables S3 and S4. Data acquisition and quantification were performed using LabSolutions LCMS software ver. 5.65 (Shimadzu). Quantitative real-time RT-PCR The preparation of RNA and quantitative real-time RT-PCR assays were performed as previously described [20]. The mouse-specific primer pairs used in this study are listed in Table S5. Western blot analysis Whole cell extracts of skeletal muscle were prepared as follows. Frozen gastrocnemius muscle was homogenized using a glass homogenizer in RIPA lysis buffer (Merck Millipore, Burlington, MA, USA) supplemented with a protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). The homogenates were centrifuged at 15,000 × g for 15 min at 4 °C, and the supernatants were collected. Protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Takara Bio, Shiga, Japan). For western blotting, 20 µg of whole cell extracts were separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were blocked with 5% skim milk in Tris-buffered saline containing 0.05% Tween-80 for 1 h at room temperature (15–25 °C). The membranes were then incubated overnight at 4 °C with primary antibodies, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using ECL Prime Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA), and band intensities were quantified using a FUSION FX chemiluminescence imaging system (Vilber, Collégien, France). The following primary antibodies were used: anti-glycerol-3-phosphate acyltransferase (GPAT) 3 (96164; Cell Signaling Technology, Danvers, MA, USA), anti-lysophospholipid acyltransferase (LPLAT) 7 (KIAA0205; Protein Express, Cincinnati, OH, USA), and anti-calnexin (10427–2-AP; Proteintech, Rosemont, IL, USA). The following HRP-conjugated secondary antibody was used: anti-rabbit IgG (7074; Cell Signaling Technology, Danvers, MA, USA). Statistical analysis For testing whether the variances between groups were equal, a two-tailed F-test was conducted. If the variances were found to be equal, Student's t-test assuming equal variances was employed using GraphPad Prism ver. 10 (GraphPad Software, San Diego, CA, USA). However, if the variances were unequal, Welch's t-test assuming unequal variances was applied. Results Muscle hypertrophy induced by 4 weeks clenbuterol administration Following 4 weeks clenbuterol administration, each muscle mass was significantly increased (Fig. 1A). To assess changes in muscle strength, four-limb grip strength was measured, and a significant increase was observed in the clenbuterol-treated group (Fig. 1B). Other data, including body weight, fat mass, water intake, food intake, and body weight-corrected limb grip strength, are shown in Fig. S1. We next analyzed myofiber types in TA. Immunohistochemical analysis using the MyHC I-, IIa-, and IIb-specific antibodies was performed to analyze the composition of myofiber types. The myofibers that were not detected with MyHC I, IIa, or IIb-specific antibodies were classified as type IIx fiber (Fig. 1C). In mixed fiber type muscle, the distribution of muscle fiber types differs between the deep region adjacent to the bone and the superficial region near the skin surface [21]. The deep region is enriched in type IIa fibers, whereas most fibers in the superficial region consist of type IIb fibers. Across the entire TA muscle, 4 weeks clenbuterol administration tended to decrease the proportion of type IIa fibers and tended to increase the proportion of type IIb fibers (Fig. 1D, P = 0.082 and 0.068, respectively). When the proportions of MyHC fiber types were analyzed separately in the deep and superficial regions, a significant reduction in type IIa fibers was observed in the deep region (Fig. 1E), whereas the superficial region exhibited a decrease in type IIx fibers accompanied by an increase in type IIb fibers (Fig. 1F). Taken together, these results suggest that 4 weeks clenbuterol administration promotes a shift toward fast-twitch fiber characteristics in mixed skeletal muscle. Next, to assess clenbuterol-induced muscle hypertrophy, we quantified the CSA of individual muscle fibers for each fiber type. Although the CSAs of type IIa, type IIx, and type IIb fibers were altered by clenbuterol administration, a significant change was observed only in the percentage increase in CSA of type IIx fibers by approximately 30% (Fig. 1G and H). The histogram of CSAs of individual muscle fibers in control mice showed a bimodal-like pattern with peaks at approximately 501–750 μm2, 751–1000 μm2, and 1251–1750 μm2, respectively (Fig. 1I, J, and K). The histogram of muscle fiber types in mice treated with clenbuterol showed a tendency for all muscle fiber groups—including type IIa, type IIx, and type IIb—to shift toward a range with larger CSA. Four weeks of clenbuterol administration induced changes in the phenotype of skeletal muscle. Male mice (7 weeks old) were administered clenbuterol for 4 weeks (Clenbuterol) or treated with vehicle (0.02% ethanol) as a control (Control) (Control: n = 6–7, Clenbuterol: n = 6). (A) Absolute skeletal muscle weights. (B) Four-limb grip strength. (C) Immunofluorescence images of myosin heavy chain (MyHC) type I, IIa, and IIb, and laminin fibers using specific antibodies in the TA. (D-F) Quantification of muscle fiber type composition based on the immunohistochemical analyses shown in (D) entire region, (E) deep region, and (F) superficial region. (G and H) Fiber cross-sectional area (CSA) (G) and relative changes in CSA (H) of different fiber types in the TA. (I-K) Distribution of CSA for each (I) type IIa, (J) IIx, and (K) IIb in the TA (Control: n = 4, Clenbuterol: n = 4). Frequency histograms show the distribution of muscle fiber CSA measured from transverse muscle sections. Each bar represents the percentage of fibers within each CSA category. Because the histogram represents pooled fiber-level data rather than individual animal-level statistics, measures of variability such as standard error of the mean (SEM) are not displayed. TA; tibialis anterior, EDL; extensor digitorum longus, Gastro; gastrocnemius, Quadri; quadriceps, N.D., not detected. Values are presented as means ± SEM. Statistical significance: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 versus Control. Glycerophospholipid remodeling in the muscle by 4 weeks clenbuterol administration To explore changes in glycerophospholipid composition associated with the fast-twitch fiber transition and hypertrophy induced by 4 weeks clenbuterol administration observed in Fig. 1, glycerophospholipid molecular species present in the TA muscle were analyzed by LC-MS. Among skeletal muscle glycerophospholipids, PC accounts for approximately 40–50% and PE for about 20% of the total glycerophospholipid pool, whereas phosphatidylinositol, phosphatidylserine, and phosphatidylglycerol together constitute less than 10% [22]. Accordingly, we performed targeted analyses of PC and PE, the most abundant glycerophospholipid classes, using MRM to quantify individual PC and PE molecular species. While no individual PC or PE species showed marked alterations, calculation of relative abundance by acyl chain composition demonstrated a significant increase in 16:0-PC and significant decreases in 18:0- and 20:4-PC in the TA muscle of clenbuterol-administered mice (Fig. 2A; Tables S6 and S7). In PE species, an increase in 16:1-PE and a decrease in 20:4-PE were observed, while 18:0-PE showed a decreasing trend (P = 0.058) (Fig. 2B). We also examined changes in PC and PE molecular species in TA following a single dose of clenbuterol, but no significant changes were observed (Fig. S2). Four weeks of clenbuterol administration induced changes in PC and PE profiles in the TA and soleus. Male mice (7 weeks old) were administered clenbuterol for 4 weeks (Clenbuterol) or treated with vehicle (0.02% ethanol) as a control (Control). Four weeks of clenbuterol administration induced changes in PC and PE profiles in the (A and B) TA and (C and D) soleus. (A and C) Proportions of each PC group to PC, sorted by acyl chain. (B and D) Proportions of each PE group to PE, sorted by acyl chain. PC; phosphatidylcholine, PE; phosphatidylethanolamine, TA; tibialis anterior. Values are presented as means ± SEM (Control: n = 7, Clenbuterol: n = 6). Statistical significance: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 versus Control. Previous studies have reported that the effects of clenbuterol on muscle fiber hypertrophy and fast-twitch fiber transitions differ among fiber types [23], [24]. In the fast-twitch EDL muscle, all type II fibers (type IIa, IIx, and IIb) undergo hypertrophy, whereas in the slow-twitch soleus muscle, hypertrophy is restricted primarily to type IIx fibers [23]. With respect to fiber-type transitions, clenbuterol-induced fast-twitch transition is more pronounced in the soleus than in the EDL, characterized by a marked reduction in type I fibers and a concomitant increase in type IIx fibers [24]. We therefore investigated glycerophospholipid remodeling in the soleus muscle, and found that the soleus muscle displayed a distinct glycerophospholipid profile, characterized by a significant increase in 16:0-PC and a marked decrease in 18:0-PC, accompanied by increases in 18:2-PC and 18:2-PE and decreases in 20:5-PC, 22:6-PC, and 20:4-PE by 4 weeks of clenbuterol administration (Fig. 2C and D). The amounts of PC and PE molecules detected in the soleus are listed in Table S8-9. Altered expression of genes and proteins involved in glycerophospholipid acyl chain determination following clenbuterol administration Glycerophospholipids are biosynthesized in the de novo pathway and change the acyl chain mainly via the remodeling pathway [7]. We examined the effects of clenbuterol administration on the expression of genes encoding acyltransferases involved in acyl chain incorporation through de novo synthesis and glycerophospholipid remodeling pathways, including four GPAT isoforms (GPAT1–4) and fourteen LPLAT isoforms (LPLAT1–14). No significant changes in GPAT or LPLAT expression were observed in the TA muscle after 4 weeks of clenbuterol administration (Fig. 3A). When evaluating gene expression, alterations may be attenuated or obscured in samples exposed to 4 weeks intervention, and therefore, assessment of acute responses is also required [25]. To examine acute changes in GPAT and LPLAT gene expression induced by a single dose of clenbuterol, we analyzed gene expression in the TA muscle. As a result, the expression levels of GPAT3 and LPLAT2, LPLAT3, LPLAT10, and LPLAT12 were significantly upregulated (Fig. 3B). Whereas most gene expression changes were approximately 1.5-fold, clenbuterol-induced upregulation of GPAT3 expression exceeded 15-fold. In contrast, genes that were significantly downregulated included GPAT1 and LPLAT1, LPLAT5, LPLAT7, LPLAT8, LPLAT11, LPLAT13, and LPLAT14. Gene and protein expression related to glycerophospholipid biosynthesis and remodeling in the skeletal muscle after 4 weeks or acute clenbuterol administration. Gene expression of enzymes involved in glycerophospholipid biosynthesis and remodeling, including GPATs and LPLATs, in the TA muscle of mice (A) after 4 weeks of clenbuterol administration and (B) after a single clenbuterol injection. (C) GPAT3 protein expression in gastrocnemius after 4 weeks of clenbuterol administration. GPAT3 protein expression levels were normalized based on the band intensity obtained from Ponceau S staining (Fig. S3). Values are presented as means ± SEM (Control: n = 5–6, Clenbuterol: n = 6, Single Control: n = 5, Single Clenbuterol: n = 5). Statistical significance: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 versus Single Control or Control. N.D.; not detected. Next, we analyzed changes in protein expression of GPAT3, which showed the greatest increase in mRNA expression by a single dose of clenbuterol administration, in skeletal muscle following 4 weeks of clenbuterol administration using Western blotting. As shown in Fig. 3C, clenbuterol administration significantly increased GPAT3 protein expression by approximately 1.5-fold. We also examined changes in LPLAT7 protein expression levels; however, commercially available antibodies were unable to clearly detect changes in LPLAT7 protein levels induced by clenbuterol administration (data not shown). Discussion Skeletal muscle is a highly plastic organ that adapts its structural and functional properties in response to external stimuli through changes in contractile proteins, organelle remodeling, and neural regulation [26], [27], [28]. Recent studies have also demonstrated that glycerophospholipid molecular diversity influences skeletal muscle phenotype, with characteristic alterations in glycerophospholipid composition accompanying muscle remodeling [9], [10], [20], [29]. For example, slow-twitch transition of fast-twitch fibers is associated with increased 18:0-PC and PE [9], whereas muscle atrophy induced by fasting or denervation increases PC and PE containing linoleate (18:2-PC and PE) [20], [29]. However, whether glycerophospholipid composition is altered during fast-twitch fiber transition and muscle hypertrophy has remained unclear. Consistent with previous reports, clenbuterol administration increased muscle mass and grip strength, while inducing fast-twitch fiber transition [15]. The present study demonstrates that fast-twitch transition, such as a decrease in the proportion of type IIa and type IIx fibers and an increase in the proportion of type IIb fibers, and hypertrophy in TA muscle induced by clenbuterol are accompanied by characteristic changes in glycerophospholipid composition. We observed an increase in 16:0-PC and a decrease in 18:0-PC in the skeletal muscle. In addition, although this study did not specifically investigate the transition of muscle fiber types, similar results were observed in the soleus muscle, where a shift toward fast-twitch fibers following clenbuterol administration has previously been reported [24]. These findings suggest that glycerophospholipid acyl-chain composition is dynamically remodeled during fast-twitch muscle adaptation. Furthermore, the altered expression of acyltransferases, such as GPAT3, involved in glycerophospholipid biosynthesis suggests that coordinated regulation of lipid metabolic enzymes may contribute to these lipidomic changes. Together, these results suggest that glycerophospholipid acyl-chain composition reflects the phenotypic state of skeletal muscle fibers and may represent a lipidomic signature of muscle fiber-type transition. Meanwhile, Ferrara et al. observed that when skeletal muscle lyso-PC levels were reduced by overexpression of lysophosphatidylcholine acyltransferase (LPCAT) 3 (recently renamed to LPLAT12), muscle metabolic characteristics tended to shift from oxidative to glycolytic [30]. Specifically, indicators associated with oxidative fibers (type IIa fibers) decreased, while indicators associated with faster-twitch fibers (type IIx and IIb fibers), which rely more on glycolytic metabolism, showed a relative increase. This suggests that there may be some relationship between muscle fiber type and glycerophospholipids, and that changes in glycerophospholipids may promote muscle fiber type transition. Further analysis using genetically modified mice will be necessary to determine whether the muscle fiber type transition induced by clenbuterol is due to changes in glycerophospholipid molecular species. With respect to the biosynthesis of 16:0- and 18:0-PC, palmitoyl-CoA or stearoyl-CoA is preferentially incorporated into the sn-1 position of glycerophospholipids during de novo glycerophospholipid synthesis [31]. The initial step of acyl chain incorporation at the sn-1 position is catalyzed by GPATs, which mediate the acylation of glycerol-3-phosphate (G3P). Four GPAT isoforms have been identified, and among them, GPAT1 and GPAT3 exhibited altered gene expression in response to single clenbuterol administration (Fig. 3B). GPAT1 and GPAT3 differ markedly in their intracellular localization and roles in lipid metabolism [32]. GPAT1, which is localized to the mitochondrial outer membrane, contributes to both triacylglycerol and glycerophospholipid synthesis and preferentially incorporates palmitoyl-CoA into G3P [32], [33]. Consistently, global GPAT1 deletion decreases 16:0-PC and PE while increasing 18:0-containing species [33], [34], indicating that reduced GPAT1 expression cannot explain the glycerophospholipid changes observed in the 4 weeks clenbuterol administration model. In contrast, the ER-localized GPAT3 predominantly promotes triacylglycerol synthesis and lipid storage [32]. GPAT3 exhibits high substrate preference for oleoyl-, palmitoyl-, and linoleoyl-CoA [35]. Recently, a preprint study reported that GPAT3 deficient cultured cells display a reduction in PC and PE species bearing palmitate at the sn-1 position, along with an increase in stearate-containing PC and PE species [36]. Although the effect was less pronounced than that observed with GPAT1 deficiency, these findings consistent with our data and suggest that clenbuterol-induced upregulation of GPAT3 contributes to increased 16:0-PC and decreased 18:0-PC. A search for transcription factor binding motifs 2 kb upstream of the GPAT3 gene start site using JASPAR (https://jaspar.elixir.no/) revealed the presence of a consensus cAMP response element binding protein (CREB) binding sequence 1.6 kb upstream. This suggests that clenbuterol administration may increase GPAT3 gene expression by activating cAMP-dependent protein kinase (Protein kinase A, PKA) signaling, promoting CREB phosphorylation, and facilitating nuclear translocation. Furthermore, in this study, since GPAT3 protein expression also increased following 4 weeks of clenbuterol administration, it was suggested that the changes in glycerophospholipid molecular species observed in skeletal muscle after clenbuterol administration could be partially explained by the increase in GPAT3 expression. Newly synthesized glycerophospholipids are optimized through the Lands’ cycle, involving de-acylation by phospholipases followed by re-acylation mediated by LPLATs. Among these enzymes, LPLAT7, LPLAT8, and LPLAT9 have been reported to catalyze acyl chain incorporation at the sn-1 position of 1-hydroxy-2-acyl-lysophospholipids (sn-1 lyso-PC) [9], [37], [38], [39], [40]. In the present study, LPLAT7 and LPLAT8 showed significant decrease in response to single clenbuterol administration (Fig. 3B). LPLAT7 is expressed at higher levels in slow-twitch muscle and has been shown in our previous study to contribute substantially to the production of 18:0-PC and PE species [9]. Therefore, the significant downregulation of LPLAT7 induced by clenbuterol may promote an increase in 16:0-PC and a decrease in 18:0-PC. Although LPLAT8 has been implicated in the generation of 16:0-containing PC and PE species [40], its reduced expression does not fully align with the glycerophospholipid changes observed after 4 weeks of clenbuterol administration. Notably, reanalysis of a publicly available RNA-seq dataset (DRA014336) revealed that LPLAT7 is more abundantly expressed than LPLAT8 in skeletal muscle [41], suggesting a dominant role for LPLAT7. Since the LPLAT7 gene is highly expressed in slow-twitch muscle fibers and its expression is increased by PGC-1α, the involvement of transcription factors that promote slow-twitch muscle development is suspected [9]. Among these, myocyte enhancer factor (MEF) 2 is known as a transcription factor that promotes slow-twitch muscle development [42], and since a MEF2-binding site exists in the 5’ upstream region of the LPLAT7 gene [9], LPLAT7 expression may increase in a MEF2-dependent manner. Regarding the regulation of MEF2 activity, Zhang et al. demonstrated that class II histone deacetylases (HDACs) act as signal-responsive transcriptional repressors of MEF2 [43]. HDAC4 and HDAC5 bind directly to MEF2 and suppress the transcription of MEF2-target genes via histone deacetylation. Ha et al. elucidated the effects of PKA signaling on this HDAC–MEF2 regulatory system [44]. They demonstrated that PKA phosphorylates HDAC5, thereby inhibiting its nuclear export and promoting its retention in the nucleus. When HDAC5 is retained in the nucleus, its association with MEF2 is maintained, thereby suppressing MEF2-dependent transcription. Thus, it was demonstrated that PKA signaling forms a pathway that negatively regulates MEF2 transcriptional activity via HDAC5. Furthermore, Backs et al. reported that when PKA is activated, HDAC4 undergoes proteolysis, generating an N-terminal fragment [45]. They demonstrated that this HDAC4 fragment binds strongly to MEF2 and acts as a transcriptional repressor, functioning as a MEF2-specific transcriptional repression mechanism; in other words, PKA signaling can sustainably suppress MEF2 activity via the cleavage product of HDAC4. These reports indicate that MEF2 transcriptional activity is precisely regulated via HDACs. While the cAMP/PKA signaling pathway activated by clenbuterol is thought to suppress MEF2 by retaining HDACs in the nucleus and generating HDAC fragments, thereby suppressing the transcription of the LPLAT7 gene. We also examined changes in LPLAT7 protein expression levels; however, commercially available antibodies were unable to clearly detect changes in LPLAT7 protein levels induced by clenbuterol administration (data not shown). In addition to changes in 16:0- and 18:0-PC and PE species, 20:4-PC, 20:4-PE, and 22:6-PC exhibited consistent alterations across multiple skeletal muscles (Fig. 2A-F). Previous studies have reported increases in 20:4- and 22:6-PC in fast-twitch muscles that undergo slow-twitch like transition in response to endurance exercise training [10], suggesting that glycerophospholipids containing polyunsaturated fatty acids are enriched in slow-twitch fibers. Accordingly, the reductions in these PC species observed following clenbuterol administration may be attributable to the induction of fast-twitch transition. However, the molecular mechanisms underlying the regulation of polyunsaturated fatty acid-containing glycerophospholipids during muscle fiber-type transitions remain to be elucidated. Collectively, the present study demonstrates that clenbuterol-induced fast-twitch transition and skeletal muscle hypertrophy are accompanied by characteristic changes in glycerophospholipid composition. We identified a lipidomic shift characterized by increased 16:0-PC and decreased 18:0-PC in skeletal muscle. These findings suggest that remodeling of glycerophospholipid acyl-chain composition may represent a previously underappreciated aspect of skeletal muscle phenotypic adaptation. Furthermore, the coordinated changes in the expression of acyltransferases involved in glycerophospholipid biosynthesis and remodeling imply that regulation of lipid metabolic pathways contributes to the establishment of muscle fiber-type-specific membrane lipid environments. Future studies will be required to determine how these lipid compositional changes influence membrane properties and muscle function during skeletal muscle transition. Abbreviations Bicinchoninic acid Cross-sectional area cAMP response element binding protein Extensor digitorum longus Glycerol-3-phosphate acyltransferase Glycerol-3-phosphate Histone deacetylase Horseradish peroxidase Liquid chromatograph-mass spectrometry Lysophosphatidylcholine acyltransferase 3 Lysophospholipid acyltransferase Myocyte enhancer factor 2 Multiple reaction monitoring Myosin heavy chain Phosphatidylcholine Phosphatidylethanolamine Proliferator-activated receptor gamma coactivator 1-alpha cAMP-dependent protein kinase Tibialis anterior CRediT authorship contribution statement Shinji Miura: Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Noriyuki Miyoshi: Writing – review & editing, Methodology. Sango Nakashima: Investigation, Formal analysis, Data curation. Satoshi Ohuchi: Investigation, Formal analysis, Data curation. Tomoki Sato: Writing – review & editing, Writing – original draft, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Yuna Suzuki: Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Funding This work was supported by Grants-in-Aid for Scientific Research (KAKENHI, No. 22K17831) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT, Tokyo); The Nakatomi Foundation (Tokyo); The Uehara Memorial Foundation (Tokyo); Grant for Young Scientists of Japan Society of Nutrition and Food Science (Tokyo) (to Tomoki Sato); Grants-in-Aid for Scientific Research (KAKENHI, No. 18H04677, 21H03362, 24K02885) from MEXT, Tokyo; a University of Shizuoka Grant for Scientific and Educational Research (to Shinji Miura). Declaration of Competing Interest The authors declare no competing interests directly related to the content of this article. Acknowledgements We are indebted to the members of the Laboratory of Nutritional Biochemistry (Graduate School of Nutritional and Environmental Sciences, University of Shizuoka) for their valuable technical assistance. Footnotes Supplementary data associated with this article can be found in the online version at doi:10.1016/j.jphyss.2026.100081. Supplementary material Supplementary material Supplementary material Supplementary material Supplementary material Data availability The data supporting the findings of this study are available from the corresponding author, SM, upon reasonable request. References Associated Data Supplementary Materials Supplementary material Supplementary material Supplementary material Supplementary material Data Availability Statement The data supporting the findings of this study are available from the corresponding author, SM, upon reasonable request.